Literature DB >> 28108536

DPP-4 Inhibitor-Related Pancreatitis: Rare but Real!

J Hans DeVries1, Julio Rosenstock2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28108536     DOI： 10.2337/dci16-0035

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  10 in total

Review 1.  Personalized Management of Type 2 Diabetes.

Authors:  Patricia R Peter; Beatrice C Lupsa
Journal:  Curr Diab Rep       Date:  2019-11-04       Impact factor: 4.810

Review 2.  Uncurtaining the effect of COVID-19 in diabetes mellitus: a complex clinical management approach.

Authors:  Shilpi Kashyap; Rajni Bala; Reecha Madaan; Tapan Behl
Journal:  Environ Sci Pollut Res Int       Date:  2021-05-21       Impact factor: 4.223

3.  Livedoid and Purpuric Skin Eruptions Associated With Coagulopathy in Severe COVID-19.

Authors:  Caren Droesch; Mytrang Hoang Do; Maria DeSancho; Eun-Ju Lee; Cynthia Magro; Joanna Harp
Journal:  JAMA Dermatol       Date:  2020-09-01       Impact factor: 10.282

4.  Effects of Sitagliptin on Pancreatic Beta-Cells in Type 2 Diabetes With Sulfonylurea Treatment: A Prospective Randomized Study.

Authors:  Ai Sato; Masahiro Takei; Kunihide Hiramatsu; Teiji Takeda; Takahide Miyamoto; Masanori Yamazaki; Yoshihiko Sato; Mitsuhisa Komatsu
Journal:  J Clin Med Res       Date:  2018-12-03

5.  Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study.

Authors:  Rimei Nishimura; Haruka Kato; Koichi Kisanuki; Akinori Oh; Shinzo Hiroi; Yoshie Onishi; Florent Guelfucci; Yukio Shimasaki
Journal:  BMJ Open       Date:  2019-03-01       Impact factor: 2.692

Review 6.  Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?

Authors:  Nordin Mj Hanssen; Karin Am Jandeleit-Dahm
Journal:  Diab Vasc Dis Res       Date:  2019-04-24       Impact factor: 3.291

7.  Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis.

Authors:  Maria Mirabelli; Eusebio Chiefari; Luigi Puccio; Daniela Patrizia Foti; Antonio Brunetti
Journal:  Int J Environ Res Public Health       Date:  2020-05-22       Impact factor: 3.390

Review 8.  Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment.

Authors:  Matilda Florentin; Michael S Kostapanos; Athanasia K Papazafiropoulou
Journal:  World J Diabetes       Date:  2022-02-15

9.  Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals.

Authors:  Jorge F A Model; Débora S Rocha; Alessa da C Fagundes; Anapaula S Vinagre
Journal:  Vet Anim Sci       Date:  2022-03-23

Review 10.  Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.

Authors:  Carolyn F Deacon
Journal:  Nat Rev Endocrinol       Date:  2020-09-14       Impact factor: 43.330
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.